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Abstract
E-cadherin protein (CDH1 gene) integrity is fundamental to the process of epithe-
lial polarization and differentiation. Deregulation of the E-cadherin function plays 
a crucial role in breast cancer metastases, with worse prognosis and shorter overall 
survival. In this narrative review, we describe the inactivating mechanisms underly-
ing CDH1 gene activity and its possible translation to clinical practice as a prognostic 
biomarker and as a potential targeted therapy.
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1  | INTRODUC TION
The E-cadherin (E-cad) gene (CDH1) [OMIM + 192090] is a calci-
um-dependent cell-to-cell adhesion molecule and tumour suppres-
sor protein that is the only germline molecular defect associated 
with hereditary diffuse gastric and lobular breast cancers.1,2 The 
E-cad protein plays a critical role in establishing and maintaining 
polarized and differentiated epithelia through intercellular adhesion 
complexes. This molecule is considered an invasion suppressor, and 
its deregulation is often found in advanced cases of some epithelial 
carcinomas.3
Deletion or deregulation of E-cad is also correlated with the infil-
trative and metastatic ability of the tumour because of disruption of 
the cadherin-catenin complex, with consequent loss of cell adhesion 
and concomitant increase in cell motility.4,5 In gastric carcinoma in 
particular, defective mechanisms of E-cad are well associated with 
cancer metastatization; patients carrying any somatic E-cad alter-
ations show the worst prognosis and shortest probability of overall 
survival (OS).6
In relation to breast cancer, regular E-cad function presents as 
an inhibitor of metastasis. It has been shown that somatic E-cad in-
activation is associated with an aggressive pattern of breast cancer, 
particularly lymphovascular invasion and metastasis in the axillary 
lymph nodes.7-10
Cancer metastatization often represents a dramatic event for 
the patient, due to the psychological impact of its worse prognosis 
and shorter OS. Prognostic molecular biomarkers are fundamental 
to assess the risk of tumour relapse after curative intent and cancer 
metastatization in this setting.
In this narrative review, we describe the principal mechanisms of 
E-cad inactivation (genetic and epigenetic) and its possible clinical 
implications for breast cancer as a prognostic and therapeutic factor.
2  | MECHANISMS OF E- C AD 
INAC TIVATION
Breast cancer's progression and capacity to invade and metastasize 
to distant sites is strongly associated with the loss of E-cad. It has 
been postulated that loss of E-cad expression is an early gatekeeper 
event in in situ lobular breast cancer and a precursor of invasive 
lobular breast cancer.7,11 Over the last several years, a number of 
mechanisms have been identified as the cause of E-cad inactivation 
in breast cancer.12-14 Inactivating mutations in the CDH1 gene have 
been frequently described and can explain a great proportion of in-
vasive lobular breast cancer cases. Indeed, one of the first studies 
addressing the contribution of CDH1 mutations to the absence of 
E-cad expression found that 55% (21 of 38 cases) of breast cancers 
from the lobular subtype harboured CDH1 genetic alterations.15 In a 
subsequent study, Berx and colleagues13 found somatic mutations of 
the E-cad gene at a comparable frequency: 56% (23 of 41) of lobular 
carcinoma cases analysed showed E-cad mutations. This high fre-
quency of CDH1 mutations in breast cancer was not reported in all 
studies, however. Huiping et al16 examined 40 lobular breast cancers 
for E-cad mutations and identified only 5 frameshift and 1 splice site 
mutations (constituting 15% of the cases in the study). In a different 
study by Droufakou et al,12 6 novel mutations were detected in a set 
of 22 invasive lobular carcinomas, accounting for 27% of the cases 
analysed. Interestingly, in the majority of these studies, mutations 
were found in combination with loss of heterozygosity (LOH) at the 
E-cad chromosomal locus, spotlighting E-cad as a tumour suppressor 
gene.12,13,16 Specifically, among the 23 mutations identified by Berx 
and colleagues,13 21 were found in combination with LOH of the 
wild typeCDH1locus. These data were further validated by Huiping 
and colleagues,16 who detected LOH at 16q22.1 in all of the lobular 
breast tumours examined by their study. Currently, it is well estab-
lished that 50% of invasive lobular carcinomas show LOH, which is 
determinant for protein dysfunction and loss of expression.12,13,17
Apart from structural genetic alterations, epigenetic modifica-
tions have also emerged as a possible cause for the impairment of 
E-cad expression and function. In particular, hypermethylation of 
the CDH1 promoter is the predominant mechanism of E-cad loss in 
multiple types of cancer, including breast cancer.18-20 In this context, 
Shargh and colleagues21 investigated the association between CDH1 
promoter methylation and E-cad expression in 50 ductal breast can-
cer cases and their respective paired normal breast samples. They 
observed that 94% of ductal breast cancers were methylated at the 
CDH1 promoter. Furthermore, they found that there was no detect-
able E-cad expression in all the cases displaying complete promoter 
methylation.
Clinically, an association between CDH1 methylation and breast 
cancer progression has also been reported. Nass et al22 examined 
111 cases of ductal breast carcinomas and observed that CDH1 
methylation was present in 31% of in situ lesions, in 52% of invasive 
tumours, and in 61% of metastatic cancers, indicating an increase of 
CpG island methylation as cells gain invasiveness and metastatic po-
tential. Later on, the impact of hypermethylation on 6 tumour sup-
pressor genes in tumour progression was evaluated using a series 
of 151 primary breast tumours, in which the CDH1 promoter was 
found to be hypermethylated in 53% of cases. Strikingly, in cases 
with sentinel lymph node metastasis, CDH1 was the most frequently 
methylated gene (90%), reinforcing the evidence that CDH1 hyper-
methylation prevails at a more advanced disease stage.23 Sebova 
and colleagues24 proposed that CDH1 hypermethylation can be 
used as a biomarker for potentially metastasizing tumours. They 
observed that CDH1 promoter hypermethylation was preferentially 
observed in breast cancer cases with positive lymph node metastasis 
and in cases from more aggressive immunohistochemical subtypes. 
A correlation between CDH1 methylation status and the prognosis 
of breast cancer patients was also explored using a series of 137 
primary breast cancers, 85 matched normal breast tissue samples, 
and 13 lung metastasis cases. It was observed that 40.9% of breast 
cancers and 61.5% of lung metastasis samples were hypermethyl-
ated in the CDH1 promoter, while none of the normal breast samples 
displayed CDH1 methylation. In addition, patients with CDH1 meth-
ylation presented significantly poor OS as well as lower disease-free 
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survival (DFS), supporting the significance of CDH1 expression as a 
predictive biomarker of poor prognosis in breast cancer.25
At the transcriptional level, several molecules are known to bind 
to specific DNA sequences of the E-boxes of the CDH1 promoter, 
repressing the transcription of E-cad and activating mesenchymal 
genes, and thus promoting the so called ‘epithelial to mesenchymal 
transition’ (EMT).26 This loss of epithelial gene expression and acti-
vation of a mesenchymal molecular profile can involve SNAIL, zinc 
finger E-box-binding (ZEB) and TWIST transcription factors, whose 
expression is critical to cancer development.27,28 In breast cancer, it 
has been reported that silencing of SNAIL increases E-cad expres-
sion and, consequently, decreases expression of mesenchymal mark-
ers, decreases tumourigenicity and inhibits the invasive behaviour 
of breast cancer cells.29 Moreover, Xiang and colleagues30 studied 
the expression of ZEB1 by immunohistochemistry in 102 breast 
carcinoma samples and found that carcinomas with high aggressive 
potential presented high levels of ZEB1. They were able to associate 
increased levels of ZEB1 with lymph node metastasis and advanced 
disease stage, proposing ZEB1 as an additional prognostic marker 
in breast carcinoma. A microarray gene expression data set from 57 
invasive human breast tumours also revealed that 70% of invasive 
lobular carcinomas, 32% of invasive ductal carcinomas, and 30% of 
mixed ductal/lobular carcinomas presented higher expression of 
TWIST when compared with normal breast tissue, awarding TWIST 
an important role in tumour metastasis.31
More recently, post-translational mechanisms, such as glyco-
sylation, have emerged as critical processes in cancer. Aberrant gly-
cosylation has itself been suggested as a new hallmark of cancer, 
since it impacts cell differentiation, adhesion and proliferation.31 In 
particular, E-cad can be post-translationally modified by O (oxygen)- 
and N (nitrogen)-glycosylation.32,33 These modifications have been 
reported to be essential for E-cad folding, trafficking and stability 
at the membrane.34-37 Aberrant O-glycosylation of E-cad in its cy-
toplasmic domain blocks its exocytosis to the cell surface, inhibiting 
E-cad-mediated cell adhesion.38 Furthermore, O-glycosylation in-
creases cell migration and metastasis mostly by decreasing E-cad at 
the surface of breast cancer cells.39 In contrast to O-glycosylation, 
which occurs at the intracellular portion of E-cad, N-glycosylation 
takes place in 4 possible sites at the extracellular domain responsible 
for homophilic interaction between 2 cadherin molecules of adja-
cent cells.33 Thus, Zhao and colleagues40 undertook a detailed study 
of the role of N-glycosylation in E-cad adhesive function and stability 
at the membrane. They demonstrated that the removal of glycans in 
specific positions reduces protein stability and modifies the compo-
sition of adherens junctions, impairing cell compaction. Supporting 
the relevance of glycolsylation in breast cancer, it was demonstrated 
that GCNT2—a gene-encoding glucosaminyl (N-acetyl) transferase 
2 that plays a critical role in glycosylation—is related to basal-like 
and metastatic phenotypes in both breast cancer cell lines of human 
and mouse origins, and of human breast tumour samples. GCNT2 
is overexpressed in highly metastatic breast cancer, and its expres-
sion correlates with adverse pathological features and progression 
of disease. Remarkably, it has been suggested that the GCNT2's 
metastasis-promoting effect is mediated through modulation of 
E-cad protein levels: the overexpression of GCNT2 decreases E-cad 
expression, whereas its down-regulation induces increased levels 
of the protein.41 Despite the low number of studies addressing the 
impact of the E-cad glycosylation pattern in breast cancer, it is clear 
that post-translational modifications can underlie the spreading abil-
ities of breast cancer cells associated with E-cad dysfunction. As 
such, abnormal glycan structures are becoming attractive in clinics 
as potential therapeutic targets or prognostic biomarkers. Figure 1 
provides an illustration of the mechanisms underlying E-cad inacti-
vation in breast cancer.
3  | E- C AD A S PROGNOSTIC BIOMARKER
Breast cancer is a highly heterogeneous disease in which even simi-
lar clinical and pathologic features lead to distinct outcomes. These 
observations indicate that staging systems based on clinical and 
pathologic findings may have reached their limit of usefulness and 
impelled the need for molecular biomarkers—as an added value—to 
predict patients' outcome and treatment. Tumour size, lymph node 
status, histological grade, and oestrogen receptor (ER), progesterone 
receptor (PR) and HER2 expression are currently evaluated as pa-
rameters to define therapy and prognosis in breast cancer patients. 
Although these factors are still essential, they do not predict breast 
cancer prognosis with high accuracy. Novel and molecular biomark-
ers are required to improve survival rates for these patients.
E-cad is a fundamental intercellular adhesion molecule that links 
with catenins forming the E-cad/β-catenin/α-catenin complex. This 
molecule interacts with the actin cytoskeleton,4 which stabilizes 
cell interaction, cell polarity and the integrity of epithelial tissue. 
Disruption of E-cad causes alteration of the intercellular junction, 
and subsequently increases cell migration ability, tumour invasion 
and metastasis. In detail, in a homeostatic situation, E-cadherin is 
expressed at the adherens junctions playing a crucial role in cell-
cell adhesion and in the polarized architecture of the tissue. CDH1 
mutations can, however, induce loss of E-cadherin function and ab-
normally activate a number of mechanisms and signalling pathways. 
Mutated proteins present severe structural abnormalities, result-
ing in protein misfolding that is recognized and degraded by endo-
plasmic reticulum-associated degradation (ERAD).42 At the plasma 
membrane, mutant proteins cannot establish the cytoplasmic cat-
enin complex, allowing its rapid internalization and degradation.43 
E-cadherin loss results in abnormal activation of EGFR and Notch 
pathways, with consequences on cell motility, invasion and resis-
tance to apoptotic stimuli.3
Several studies have evaluated the potential clinical implica-
tions of E-cad inactivation in breast cancer. A recent meta-analysis 
comprising 33 retrospective studies including 7353 breast cancer 
patients evaluated the association of E-cad and OS, DFS and clinico-
pathologic factors in breast cancer.44 In this study, reduced E-cad ex-
pression on membrane was significantly associated with OS (hazard 
ratio [HR] 1.57, 95% confidence interval [CI] 1.17-2.10) and DFS (HR 
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1.37, 95% CI 1.07-1.75). Furthermore, the down-regulated expres-
sion of E-cad was correlated with tumour size, lymph node status, 
TNM stage and histological grade. In detail, E-cad low expression 
was significantly associated with lymph node status (positive vs neg-
ative: odds ratio [OR] 1.55, 95% CI 1.15-2.10), tumour size (≥2 cm vs 
<2 cm, OR 1.38, 95% CI 1.18-1.60), histological grade (II–III vs I: OR 
1.44, 95% CI 1.06-1.96) and TNM stage (T3/T4 vs T1/T2: OR 2.44, 
95% CI 1.75-3.41).
These results herein reported may change the paradigm thus far 
described for somatic E-cad deficiency. The most striking finding 
was that patients with E-cad low expression (presenting tumours 
with structural alterations) had the worst OS. Molecular variables 
such as CDH1 alterations may be crucial to predict the survival of 
breast cancer patients.8
The presence of CDH1 epigenetic and structural alterations 
in a diagnostic/pre-operative biopsy may provide clinically use-
ful information to improve patient management, particularly to 
infer the prognosis of breast cancer and the pattern of tumour 
dissemination.
4  | POTENTIAL ROLE OF E- C AD A S A 
THER APEUTIC TARGET
To date, E-cad is not a molecular target for therapeutic intervention; 
however, in vitro studies have demonstrated that germline E-cad 
function can be restored upon targeted treatment. Important novel 
E-cad cross-talk mechanisms are described. Growth factor signals 
are hyperactivated upon E-cad loss, regardless of somatic activating 
mutations in downstream effectors. In particular, the PI3K/Akt path-
way is activated upon E-cad loss in the absence of specific oncogenic 
mutations. Interestingly, it has been demonstrated in vitro that lobu-
lar breast cancer cells are sensitive to pharmacological inhibition of 
Akt, using ATP competitor AZD5363 and two allosteric inhibitors, 
MK2206 and VIII. The strongest reduction in term of growth and 
survival for cancer cells was observed for MK2206 Akt inhibitor.45 
Recently, Bajrami et al46 identified a synthetic lethal interaction 
between E-cad and ROS1. ROS1 gene rearrangements represent 
well-known cancer-related aberrations and therapeutic targets of 
approved drugs. The Authors showed that ROS1 inhibition in E-cad-
defective breast tumour cell lines and patient-derived breast tumour 
xenografts resulted in tumour cell death. This evidence suggests a 
possible role for ROS1 inhibitors in the treatment of patients with 
E-cad-defective tumours and may represent a foundational element 
for future ad hoc translational studies and clinical trials. Accordingly, 
a phase II study evaluating the effect of the combination of ROS1-
targeting drugs crizotinib and fulvestrant in advanced E-cad nega-
tive, lobular breast cancer or diffuse gastric cancer is ongoing.47
The heterodimer E-cad-epidermal growth factor receptor (EGFR) 
complex is another attractive therapeutic target. The presence of 
extracellular E-cad mutations disturbs the stability of E-cad-EGFR 
heterodimers, allowing for receptor activation by the ligand and 
consequent activation of the RhoA signalling pathway, accompanied 
by enhanced cell motility. Upon interaction with EGFR, E-cad exerts 
an inhibitory function that modulates the kinase activity of the re-
ceptor in an adhesion-independent manner. The extracellular E-cad 
mutants, by reducing its affinity for EGFR, increase the fraction of 
unbound EGFR, which can thus be activated, resulting in enhanced 
cell motility. This effect is transmitted through the activation of 
RhoA.48 Further study is needed to clarify the role of HER2 in this 
pathway and the effect of targeted treatment using HER2 inhibitors 
(ie trastuzumab).
F I G U R E  1   Mechanisms underlying 
E-cad inactivation in breast cancer. Loss 
of E-cad expression and the spreading 
abilities of breast cancer cells have been 
associated with mutations in CDH1 
gene, loss of heterozygosity at the E-cad 
chromosomal locus, hypermethylation 
of the CDH1 promoter, transcriptional 
repression and post-translational 
modifications, such as aberrant 
glycosylation
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5  | HOW TO MANAGE E- C AD IN THE 
CLINIC AL SET TING
E-cad may play a potential strategic role in the clinical manage-
ment of breast cancer patients as a predictor of prognosis and 
survival. In this review, we analyzed several studies reporting 
that E-cad dysfunction is associated with worse prognosis and 
shorter OS. Although mechanisms of CDH1 inactivation are still 
complex to manage routinely, it is reasonable to evaluate E-cad 
expression in breast tumours using standard methods, such as im-
munohistochemistry. We have already demonstrated that CDH1 
inactivation is a suitable predictive biomarkers of prognosis in 
gastric cancer's patients. In particular, the worst patient survival 
rate among all cases analysed was seen in patients with tumours 
carrying CDH1 structural alterations.6
In normal breast tissue, epithelial cells show strong and complete 
membranous expression of E-cad.49 Among breast cancers, nearly 
90% of invasive lobular carcinomas display complete or partial loss 
of E-cad immunohistochemical expression that is considered an 
important (but not necessary) diagnostic feature for this histologi-
cal subtype (Figure 2).50-52 However, aberrant E-cad immunoreac-
tivity such as complete absence or reduced membranous staining, 
and punctate, or cytoplasmic expression have been observed in 
other breast cancer subtypes.53 Given the absence of standardized 
methods, different studies have used variable antibodies and scor-
ing criteria for the immunohistochemical analysis of E-cad. These 
F I G U R E  2   Differences in E-cad immunoreactivity in breast cancer. Representative micrographs of lobular carcinoma with no 
immunohistochemical expression of E-cad (dashed arrow in A, left) and adjacent normal ducts with normal strong membranous E-cad 
staining (full arrow in A, right); invasive breast cancers, no special type showing partial loss (B) and strong (C) membranous immunoreactivity 
for E-cad. Original magnification 200×. E-cad, E-cadherin
A B C
F I G U R E  3   Core biopsy is the principal approach for breast cancer diagnosis. Histopathology and immunohistochemistry are performed 
on breast biopsy; E-cad expression is classified as ‘normal’, ‘aberrant’ or ‘absent’. Genetic or epigenetic mechanisms are underlying aberrant 
or absent E-cad expression. Patients carrying any somatic genetic/epigenetic defect are classified as ‘high risk’ for breast cancer and carry 
a worse prognosis. A personalized and intensive screening (follow-up) is proposed for those patients for early identification of any breast 
cancer relapse
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variabilities may subtend the differences observed in the clinical 
relevance of aberrant E-cad expression.44,54 Indeed, the validation 
of a robust and reproducible method for the assessment of immu-
nohistochemical expression of E-cad is fundamental to translate 
these findings to the clinical setting. In this scenario, aberrant/nega-
tive immunohistochemical expression may lead to the evaluation of 
genetic and epigenetic factors. Breast cancer patients carrying any 
somatic alterations would then be classified as ‘high risk’ for breast 
cancer relapse. A multidisciplinary team can organize a personalized 
follow-up, aiming to reduce breast cancer mortality and improve 
prognosis (Figure 3).
6  | CONCLUSION
In this narrative article, we have provided evidence for the aggres-
sive patterning of E-cad deficiency in breast cancer metastatization. 
This pathway may influence the staging and treatment of patients 
with breast cancer.
There currently is a substantial level of interest in the com-
bination of molecular targeting and prognostic biomarkers for 
patients with clinically worse disease. Integrated clinical and mo-
lecular staging will ultimately serve, in the near future, as the basis 
for generation of informed treatment decisions along the entire 
prognosis spectrum. Eventually, this and other related studies 
will help clinicians to identify patients with tumours who have 
potential worse prognoses and to identify the clinical scenarios 
in which targeted therapies should be combined with ‘traditional’ 
agents with the goal of curing greater numbers of patients with 
breast cancer.
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